VXRT News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

VX

Mkt Cap

N/A

Volume

N/A

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance EnhancementsVaxart resolved a proxy contest by entering a cooperation agreement with a stockholder group. The company will appoint a mutually agreed independent director within 90 days and form new board committees focused on stockholder engagement and clinical/regulatory affairs. The stockholder group withdrew its director nominations in exchange for enhanced corporate governance measures.GlobeNewswire Inc. · Jul 1, 2026

Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAYVaxart is urging shareholders to vote for all six of its director nominees on the WHITE proxy card ahead of its July 16, 2026 Annual Meeting. The company highlights strategic progress on its oral vaccine pipeline, including Phase 2b COVID-19 trials and partnerships with Dynavax, while defending its board against dissident nominees it claims lack relevant biotech expertise. Vaxart has made multiple settlement offers to resolve the proxy contest.GlobeNewswire Inc. · Jun 26, 2026

3 Stocks Under $5 With Strong Analyst Upside PotentialThe article highlights three sub-$5 stocks with positive analyst sentiment and significant upside potential: Grab Holdings (emerging market play with 54% upside target), Vaxart Inc. (clinical-stage biotech with oral vaccine platform and 233% upside), and ThredUp Inc. (online consignment platform with 190% upside target). All three benefit from favorable analyst ratings despite recent pullbacks, with expectations for growth in 2026 as money potentially flows back into small-cap and speculative stocks.Investing.com · Feb 24, 2026

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase ProgramDynavax reported strong Q3 2025 financial results, with HEPLISAV-B vaccine revenue increasing 13% to $90 million. The company entered an exclusive license agreement with Vaxart for an oral COVID-19 vaccine and authorized a new $100 million share repurchase program.Benzinga · Nov 5, 2025

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine ProgramDynavax Technologies has entered an exclusive worldwide license agreement with Vaxart to develop and commercialize an oral COVID-19 vaccine candidate, paying $25 million upfront and investing $5 million in equity, with potential future milestone payments.Benzinga · Nov 5, 2025

Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025Vaxart will present research on its oral pill vaccine candidates for norovirus and COVID-19 at the World Vaccine Congress Europe 2025 in Amsterdam, highlighting advances in its clinical-stage vaccine development platform.GlobeNewswire Inc. · Oct 8, 2025

Concerned Vaxart Stockholders Condemn Board’s Decision to Adjourn Reverse Stock Split Vote at Special MeetingA group of Vaxart stockholders criticized the company's board for adjourning a special meeting to vote on a reverse stock split, alleging manipulation and delay tactics despite achieving a voting quorum.GlobeNewswire Inc. · Sep 10, 2025

Vaxart Announces Adjournment of Special Meeting of StockholdersVaxart has adjourned its 2025 special stockholder meeting to September 19, 2025, providing more time for stockholders to consider recent Board composition changes and potential governance modifications. The reverse stock split proposal was not voted on at the original September 5th meeting.GlobeNewswire Inc. · Sep 8, 2025

Vaxart Granted Extension by Nasdaq to Regain ComplianceVaxart received a Nasdaq Hearings Panel decision granting an extension to regain compliance with the Nasdaq Bid Price Rule by October 17, 2025, requiring stockholder approval for a reverse stock split by September 5, 2025.GlobeNewswire Inc. · Aug 29, 2025

OTC Markets Group Welcomes Vaxart, Inc. to OTCQXVaxart, a clinical-stage biotechnology company, has qualified to trade on the OTCQX Best Market after previously trading on NASDAQ. The company focuses on developing oral recombinant vaccines for various diseases including coronavirus, norovirus, and influenza.GlobeNewswire Inc. · Jul 8, 2025

VX

VXRTVAXART INC

VXRT

Pay with—

Available Balance0.00

Your PositionYou don't own any VXRT yet.

Related Tickers

Earnings